CYP2C9 and VKORC1 gene polymorphism is inessential for bleeding development under conditions of oral application of anticoagulant acenocoumarol in Russian patients at high risk of thromboembolic complications

Bulletin of Experimental Biology and Medicine

Volumn 153, Issue 6, 2012, Pages 887-889

  Sychev, D V ^a,b,c   Ignatyev, I V ^c   Emelyanov, N V ^c   Milovanova, V V ^c   Kossovskaya, A V ^c   Kukes, I V ^b   Tashenova, A I ^a   Kukes, V G ^a,b,c  

^a INSTITUTE OF PHARMACOLOGY   (Russian Federation)

^b I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^c N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

Anticoagulants; Cytochrome P 450; Genetic polymorphism; Hemorrhages; Pharmacogenetics

Indexed keywords

ACENOCOUMAROL; CYTOCHROME P450 2C9; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; BLEEDING; COHORT ANALYSIS; CYTOCHROME P 450 2C9 GENE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; GENE; GENE LOCUS; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RUSSIAN FEDERATION; THROMBOEMBOLISM; TREATMENT DURATION; VITAMIN K EPOXIDE REDUCTASE PROTEIN COMPLEX SUBUNIT 1 GENE; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; GENOTYPING TECHNIQUE; HEART ATRIUM FIBRILLATION; INTERNATIONAL NORMALIZED RATIO; METABOLISM; RISK;

ACENOCOUMAROL; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ATRIAL FIBRILLATION; GENETIC LOCI; GENOTYPE; GENOTYPING TECHNIQUES; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; RISK; RUSSIA; THROMBOEMBOLISM;

EID: 84871642227     PISSN: 00074888     EISSN: 15738221     Source Type: Journal    
DOI: 10.1007/s10517-012-1851-0     Document Type: Article

References (14)

1. V. L. Zagorskaya, I. V. Ignatyev, E. S. Kropacheva, et al., Klin. Farmakol. Farmakoekonom., No. 1, 29-33 (2008).
2. V. G. Kukes and D. A. Sychev, Remedium, No. 3, 28-32 (2008).
3. Yu. A. Mikheeva, E. S. Kropacheva, I. V. Ignatyev, et al., Kardiologiya, No. 3, 52-57 (2008).
4. E. P. Panchenko and E. S. Kropacheva, Prevention of Thromboembolism in Patients with Atrial fibrillation [in Russian], Moscow (2007).
5. C. Geisen, M. Watzka, K. Sittinger, et al., Thromb. Haemost., 94, No. 4, 773-779 (2005).
6. F. Kamali, Curr. Opin. Hematol., 13, No. 5, 357-361 (2006).
7. L. S. Kaminsky and Z. Y. Zhang, Pharmacol. Ther., 73, No. 1, 67-74 (1997).
8. C. N. Markatos, E. Grouzi, M. Politou, et al., Pharmacogenomics, 9, No. 11, 1631-1638 (2008).
9. V. Michaud, M. C. Vanier, D. Brouillette, et al., Clin. Pharmacol. Ther., 83, No. 5, 740-748 (2008).
10. E. A. Millican, P. A. Lenzini, P. E. Milligan, et al., Blood, 110, No. 5, 1511-1515 (2007).
11. A. E. Rettie, F. M. Farin, N. G. Beri, et al., Brit. J. Clin. Pharmacol., 62, No. 5, 617-620 (2006).
12. T. Shalekamp, B. P. Brasse, J. F. Roijers, et al., Clin. Pharmacol. Ther., 80, No. 1, 13-22 (2006).
13. J. B. Talmage, Arterial Embolism and Thrombosis. MDGuidelines (2009). http://www.mdguidelines.com/arterial-embolismand-thrombosis.
14. M. Torn, W. L. Bollen, F. J. van der Meer, et al., Arch. Intern. Med., 165, No. 13, 1527-1532 (2005).